Unicycive Therapeutics, Inc.
UNCY evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for UNCY—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · UNCY
Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on in-licensing and developing therapies for renal diseases, with lead programs targeting acute kidney injury (AKI) and hyperphosphatemia.
Key risk: Need for additional capital
BioSniper Score
Based on 4 of 6 signals
Financial data as of Jun 30, 2026.
Tracking 2 pipeline candidates for Unicycive Therapeutics, Inc..
Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on in-licensing and developing therapies for renal diseases, with lead programs targeting acute kidney injury (AKI) and hyperphosphatemia.
- Unicycive's business model is to license technologies and drugs for development, regulatory approval, and commercialization in global markets [sec_mda · as of 2026-08-12].
- The company's lead candidate, UNI-494, is positioned as a potential first-in-class drug for acute kidney injury (AKI), a condition with high unmet medical need [sec_mda · as of 2026-08-12].
- As of June 30, 2026, the company reported cash and equivalents of $44.2 million and shareholders' equity of $30.2 million [sec].
- Unicycive has incurred significant operating losses, with net losses of $36.7 million and $26.6 million for the years ended December 31, 2024 and 2025, respectively [sec_mda · as of 2026-03-30].
- As of December 31, 2025, the company had an accumulated deficit of $127.8 million [sec_mda · as of 2026-03-30].
What works
- Unicycive's management team has a broad network, expertise in the biopharmaceutical industry, and a successful track record, which may provide an advantage in identifying and bringing in assets [sec_mda · as of 2026-08-12].
- If approved, UNI-494 has the potential to be a first-in-class drug for AKI, addressing a high unmet medical need where patients require renal transplant or lifelong dialysis [sec_mda · as of 2026-08-12].
- The company believes its current cash is sufficient to fund operations for more than 12 months from the date of its latest report, indicating near-term financial stability [sec_mda · as of 2026-03-30].
What to weigh
- Unicycive has a history of significant operating losses, with net losses of $36.7 million and $26.6 million for 2024 and 2025, and an accumulated deficit of $127.8 million as of December 31, 2025 [sec_mda · as of 2026-03-30].
- The company anticipates needing substantial additional capital to fund clinical trials and development, and there is no assurance that financing will be available on acceptable terms [sec_mda · as of 2026-08-12].
- Unicycive has not yet generated any product revenue, and its ability to do so depends on successful development, regulatory approval, and commercialization of its product candidates [sec_mda · as of 2026-08-12].
- The company's business model relies on in-licensing, which carries risks related to the availability and cost of attractive assets [sec_mda · as of 2026-08-12].
From the filings
Quoted directly from source documents.
UNI-494 is positioned as a potential first-in-class drug for AKI with high unmet need.
“If approved, UNI-494 has the potential to be a first-in-class drug for the treatment of AKI.”
SEC MD&A · August 12, 2026
The company has incurred significant operating losses and accumulated deficit.
“Our net losses were $36.7 million and $26.6 million for the years ended December 31, 2024 and 2025 respectively. As of December 31, 2025, we had an accumulated deficit of $127.8 million.”
SEC MD&A · March 30, 2026
Management believes current cash is sufficient for at least one year of operations.
“Based on our current level of expenditures, we believe that we have sufficient resources such that there is not substantial doubt about our ability to continue operations for at least one year after the date that these financial statements are available to be issued.”
SEC MD&A · August 12, 2026
The company's business model is to in-license and develop drugs.
“Our business model is to license technologies and drugs in order to pursue development, regulatory approval, and commercialization of those products in global markets.”
SEC MD&A · August 12, 2026
Risks & what to watch (4)›
Key risks
- Need for additional capital — The company will need substantial additional capital to complete clinical trials and development; financing may not be available on acceptable terms [sec_mda · as of 2026-08-12].
- No product revenue yet — Unicycive has not generated any product revenue and depends on successful development and regulatory approval of its candidates [sec_mda · as of 2026-08-12].
- History of operating losses — The company has incurred significant net losses and an accumulated deficit of $127.8 million as of December 31, 2025 [sec_mda · as of 2026-03-30].
- Dependence on in-licensing — The business model relies on in-licensing technologies, which carries risks related to asset availability and cost [sec_mda · as of 2026-08-12].
What to watch
- Progress of UNI-494 clinical trials for AKI and any regulatory updates [sec_mda · as of 2026-08-12].
- Ability to secure additional financing through equity, debt, or partnerships to fund operations and development [sec_mda · as of 2026-08-12].
- Changes in cash position and burn rate relative to the $44.2 million reported as of June 30, 2026 [sec].
- Any updates on the company's other product candidates or pipeline developments [sec_mda · as of 2026-08-12].
Sources: SEC MD&A · Generated August 13, 2026 · How we verify sources →
Run Unicycive Therapeutics, Inc. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Unicycive Therapeutics, Inc. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 4 of 6 signals · derived from public data
25.1 months
D/E 0.35 · 0% dilution
Lead: BLA Filed
2 candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Pipeline
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
46
Total value held
$44.9M
| Holder | Shares | Value |
|---|---|---|
| vanguard capital management llc | 1,622,860 | $10.7M |
| millennium management llc | 1,399,348 | $9.2M |
| great point partners llc | 796,558 | $5.2M |
| susquehanna international group, llp | 598,319 | $3.9M |
| citadel advisors llc | 344,741 | $2.3M |
| geode capital management, llc | 203,744 | $1.3M |
| morgan stanley | 188,182 | $1.2M |
| jane street group, llc | 156,143 | $1.0M |
| marshall wace, llp | 154,938 | $1.0M |
| dauntless investment group, llc | 147,087 | $968K |
Showing top 10 of 46 institutional holders of Unicycive Therapeutics, Inc.. Open the full 13F history after sign-in.
Short Interest
as of Apr 30, 2026- % of float
- 8.8%
- Days to cover
- 4.1
- Shares short
- 2,161,598
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
UNCY short interestGovernance
Frequently asked questions
What is the AI investment thesis for Unicycive Therapeutics, Inc.?
Unicycive Therapeutics, Inc. is a clinical-stage biotechnology company focused on in-licensing and developing therapies for renal diseases, with lead programs targeting acute kidney injury (AKI) and hyperphosphatemia.
What is Unicycive Therapeutics, Inc.'s lead drug candidate?
Unicycive Therapeutics, Inc.'s most advanced tracked candidate is oxylanthanum carbonate (BLA Filed) for hyperphosphatemia in CKD patients on dialysis.
Who is the CEO of Unicycive Therapeutics, Inc.?
Dr. Shalabh K. Gupta M.D., MPA is the chief executive officer of Unicycive Therapeutics, Inc. (UNCY).
Where is Unicycive Therapeutics, Inc. headquartered?
Unicycive Therapeutics, Inc. (UNCY) is headquartered in Mountain View, CA, United States.
What therapeutic areas does Unicycive Therapeutics, Inc. focus on?
Unicycive Therapeutics, Inc. develops therapies across Nephrology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.